External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial.
Masafumi OnoHideyuki KawashimaHironori HaraAmr S GamalRutao WangPatrick W SerruysNeil O'LearyOsama SolimanJan J PiekRobert-Jan van GeunsPeter JüniChristian W HammMarco ValgimigliPascal VranckxStephan WindeckerPhilippe Gabriel StegKeith Aa FoxYoshinobu OnumaPatrick W J C SerruysPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)
The GRACE risk score 2.0 is valuable in discriminating high risk ACS patients, however, the recalibration of the score is recommended for better risk stratification. There is no significant differences in efficacy and safety of ticagrelor monotherapy across the three GRACE risk strata.
Keyphrases
- acute coronary syndrome
- end stage renal disease
- ejection fraction
- newly diagnosed
- clinical trial
- chronic kidney disease
- percutaneous coronary intervention
- prognostic factors
- study protocol
- open label
- phase iii
- patient reported outcomes
- randomized controlled trial
- phase ii
- st elevation myocardial infarction
- combination therapy
- st segment elevation myocardial infarction
- coronary artery disease
- patient reported